Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LYS006 + tropifexor
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LYS006 + tropifexor is a combination drug under investigation primarily for the treatment of non-alcoholic steatohepatitis (NASH) and related liver diseases. - **LYS006** is an investigational small molecule that acts as a leukotriene A4 hydrolase (LTA4H) inhibitor, targeting inflammation pathways to reduce liver inflammation and fibrosis. - **Tropifexor** (also known as LJN452) is a potent, selective farnesoid X receptor (FXR) agonist developed by Novartis. FXR activation regulates bile acid metabolism, reduces liver fat accumulation, inflammation, and fibrosis. The combination aims to leverage distinct mechanisms—anti-inflammatory effects from LYS006 and metabolic/fibrotic modulation from tropifexor—to improve outcomes in fatty liver disease including NASH.
- Other names
- LYS006 + tropifexor
02
Targets
LTA4H (Leukotriene A4 hydrolase)FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on LYS006 + tropifexor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LYS006 + tropifexor.